

CURRICULUM VITAE

Patricia A. Gabow, M.D.

During a 40 year medical career, Dr. Patricia Gabow was an academic nephrologist, physician administrator, and contributor to national health policy. As a nephrologist she was a clinician, teacher, and investigator with emphasis on fluid and electrolyte balance and autosomal dominant polycystic kidney disease.

She was Principal Investigator on the largest clinical NIH Program Project Grant in Polycystic Kidney Disease for 15 years which produced seminal observations. She authored over 150 articles and book chapters. As a physician leader she served as Director of Medical Services (Chair), Medical Director (Chief Medical Officer) and finally as the CEO of Denver Health, a large integrated public health care system. During her leadership of Denver Health she led the transformation of a struggling public hospital system into a model integrated, high quality, fiscally stable system. This was accomplished in five steps: managing finances to put the system in black where it remained for the 20 years of her leadership despite providing \$4.7 billion of uninsured care; moving the entire integrated delivery system from a city government department which it had been for 135 years to an independent, governmental entity, enabling flexibility and innovation while maintaining public accountability; investing over \$300 million dollars in the physical plant creating state of the art facilities for vulnerable populations; investing over \$400 million in information technology providing robust data and tools to improve quality, accountability and efficiency; and creating and adopting innovations such as advice nurse lines, school-based clinics, standardized computer order sets, and Toyota Production/Lean to improve the accessibility, quality, and cost of care by adapting tools from other industries. Dr. Gabow's contributions to national health policy are reflected in her appointments to the Commonwealth Commission on a High Performing Health System, the federal Medicaid and CHIP Payment and Access Commission (MACPAC, 17 members), the Robert Wood Johnson Foundation Board, the National Governors' Association Health Advisory Committee, and the Aspen Group. She is a Professor of Medicine at the University of Colorado School of Medicine.

Current Status	Consultant Retired from Denver Health (September 2012)
Recent Positions:	CEO, Denver Health 1992-2012
Academic Status:	Professor of Medicine University of Colorado School of Medicine 1987 - Present
Current Address:	141 Dahlia St. Denver, CO 80220

09/21/2014

Marital Status:		Married to Harold N. Gabow, 1971 (Maiden name: Patricia A. Acquaviva)
Children:		Tenaya Louise Aaron Patrick
Education:	1961-1965 1965-1969	Seton Hill College, Greensburg, Pennsylvania (B.A., Biology) University of Pennsylvania School of Medicine (M.D.)
Postgraduate Training and Appointments:	1969-1970 1970-1971 1971-1972 1972-1973 1973-1974 1974-1979 1979-1987 1987-Present	Internship in Medicine, Hospital of the University of Pennsylvania Residency in Internal Medicine, Harbor General Hospital Renal Fellowship, San Francisco General Hospital Renal Fellowship, Hospital of the University of Pennsylvania Instructor in Medicine, Division of Renal Diseases, University of Colorado Health Sciences Center Assistant Professor of Medicine, Division of Renal Diseases, University of Colorado Health Sciences Center Associate Professor of Medicine, Division of Renal Diseases, University of Colorado Health Sciences Center Professor of Medicine, Division of Renal Diseases, University of Colorado Health Sciences Center
Positions Held:	1973-1981 1976-1981 1981-1991 1989-1992 1992-1997 1997-2008 2008-2012 2013-present	Chief, Renal Disease, Denver Health and Hospitals, Denver, Colorado Clinical Director, Department of Medicine, Denver Health and Hospitals, Denver, Colorado Director of Medical Services, Denver Health and Hospitals, Denver, Colorado Deputy Manager of Medical Affairs (CMO), Denver Health and Hospitals, Denver, Colorado Manager (Chief Executive Officer) and Medical Director (CMO), Denver Health and Hospitals, Denver, Colorado Chief Executive Officer and Medical Director (CMO), Denver Health and Hospital Authority, Denver, Colorado Chief Executive Officer, Denver Health and Hospital Authority, Denver, Colorado Senior Advisor, Simpler Consulting
Award and Honors	1969 1976	Alpha Omega Alpha Kaiser Permanente Award for Excellence in Teaching

1977-1981	American Heart Association Teaching Scholar
1982	National Board of the Medical College of Pennsylvania Annual Award to an Outstanding Woman Physician
1983	Kaiser Permanente Nominee for Excellence in Teaching Award
1990	Seton Hill College Distinguished Alumna Leadership Award
1994-2004, 2007-2009	Best Doctors in America
1998	Women of Distinction Award--Mile Hi Council of Girl Scouts, Denver, Colorado
1998	A.N. Richards Distinguished Achievement Award in Nephrology, University of Pennsylvania School of Medicine
2000	Florence Rena Sabin Award, Nationally Recognized Medical Educator and Public Health Advocate, University of Colorado Health Sciences Center
2000	The Nathan Davis Award for Career Public Servant at the Local Level, American Medical Association, Washington, DC
2001	Good Housekeeping Women in Government Award
2001 - 2004	Who's Who in Denver Business, The Denver Business Journal
2004	Colorado Women's Hall of Fame
2004	Ohtli Award from Mexican Government for Service to Mexican Citizens Living Abroad
2005	Health Care Heroes of Colorado, Health Care for All Colorado Foundation
2005,2009	100 Most Powerful People in Healthcare, Modern Healthcare
2005, 2009	The Top 25 Women in Healthcare, Modern Healthcare
2005	Health Care Industry Leader, Denver Business Journal
2005	Women Who Make a Difference, International Women's Forum and Colorado Women's Forum
2005	Outstanding Women in Business, Denver Business Journal
2007,2009	The Top 50 Most Powerful Physician Executives in Healthcare, Modern Healthcare
2007	Unique Woman of Colorado Award, Women's Foundation of Colorado
2007	Spirit of Denver Award, League of Women Voters
2008	National Center for Healthcare Leadership Award, honoring a lifetime of work to improve the field of healthcare leadership
2009	Master, American College of Physicians
2009	Honorary Degree, Doctor of Science, University of Colorado
2009	Women Who Have Changed the Heart of the City, Denver Rescue Mission
2009	Lifetime Achievement Award, Denver Business Journal Champions in Health Care
2010	Fourteenth Annual Robert W. Schrier Award of Excellence,

		University of Colorado Denver, School of Medicine, Department of Medicine
2010		Lifetime Achievement Award, Bonfils-Stanton Foundation
2010		University of Denver Honorary Degree
2010		Becker's Hospital Review: One of the 256 Hospital and Healthcare Industry Leaders to Know
2010		Innovators in Health Award, New England Healthcare Institute
2010		Becker's Hospital Review: 52 Women Hospital & Healthcare Leaders
2010		David E. Rodgers Award, Association of American Medical Colleges
2011		American Red Cross - Denver Chapter for Healthcare Lifetime Achievement Award
2011		One of the 50 Most Influential Physician Executives in Healthcare, Modern Healthcare
2011		Denver's 2011 Healthcare Leader of the Year, Denver Business Journal
2012		HealthExecNews.com: One of the Most Powerful Women in Healthcare
2012		Health Quality Leader, National Committee for Quality Assurance
2012		Excellence in Public Health Practice by an Individual, Colorado School of Public Health
2012		Induction to Association for Manufacturing Excellence Hall of Fame
2013		Awarded Rockefeller Foundation Academic Writing Residency Bellagio, Italy

Specialty

Certification:	1972	American Board of Internal Medicine
	1976	Nephrology Boards

Licensure:	1969	National Boards of Medical Examiners
	1970	California State License
	1974 - Present	Colorado State License

Invited

Membership:	1990-2000	Western Association of Physicians
	1990-Present	Women's Forum of Colorado, Inc.
	1994-Present	Association of American Physicians

Boards/Commissions

National:	1984-1996	Member, Scientific Advisory Board, Polycystic Kidney Disease Research Foundation (Chairman 1991-1996)
	1985	National Kidney Foundation, Co-Chairperson on

1991-1994	Hereditary, Urologic and Infectious Disease Member, Scientific Advisory Board, National Kidney Foundation
1991-1993	President, Council on Polycystic Kidney Disease, National Kidney Foundation
1993-1998	Member, National Public Health and Hospitals Institute Board (Chairman 1996-1998)
1994-2001	Executive Committee, National Association of Public Hospitals (Chairman 1998)
2003-2005	The Sullivan Commission
2003-2011	National Public Health & Hospital Institute
2005-Present	The Commonwealth Fund, Commission on High- Performance Health System
2008-2012	Center for Healthcare Quality and Payment Reform
2008-2012	New America Foundation, Health CEOs for Health Reform
2009-2012	National Center for Healthcare Leadership
2010-Present	Medicaid and CHIP Payment and Access Commission (MACPAC)
2012-Present	Health Advisory Board National Governors' Association
2013-Present	Robert Wood Johnson Foundation Trustee
2014-Present	Aspen Group

Committees

National:	1985, 1987	NIH Research in PKD Meeting for Planning
	1991-1993	Member Subcommittee, American College of Physicians, Medical Knowledge Self-Assessment Program in Nephrology
	1998-2000	Institute of Medicine: Committee on the Changing Market Managed Care and the Future Viability of Safety Net Providers
	2004	Institute of Medicine: Redesigning Health Insurance Benefits, Payments and Performance Improvement Programs: Subcommittee on Performance Measures and Quality Improvement Organizations
	2012 -Present	Institute of Medicine Roundtable on Value and Science- Driven Health Care
	2013-Present	High Value Healthcare Collaborative- Advisory Committee

Selected

Presentations:	1991	Testimony before Physician Payment Review Commission, Washington, DC
	1991	Testimony before Senate Democratic Policy Committee
	1992	Institute of Medicine Workshop on Genetic Diagnosis, Testing and Screening Services
	1992	American Association for the Advancement of Science, Conference on Ethical and Legal Complications of Large

- 1993 Pedigree Research, Charleston, SC
National Association of Counties (NACo) on County Governments and Health System Reform
- 1993 The Robert Wood Johnson Foundation 20th Anniversary Commemorative Conference Panel entitled "Health Investments for the Future: Changing Colorado's Portfolio"
- 1993 Intergovernmental Cooperation on Urban Violence, City/State/Federal Conference, entitled "Colorado's Call To Action: Working Together Against Urban Violence"
- 1995 Congressional Testimony, Medicare and Medicaid
- 1997 Robert Wood Johnson Symposium, Philadelphia, PA: Medicaid Managed Care
- 1998 Alpha Center, Los Angeles, CA: Providing a Social Service/Mission in a Competitive Market: Challenges for the Safety Net
- 2000 SMS National Meeting, Denver, CO: Patient Care, Physicians and Information
- 2000 Academy for Health Services Research and Health Policy, Milwaukee, WI: "Strengthening the Healthcare Safety Net"
- 2000 Health Research and Educational Trust, Westminster, CO: "Beyond the Barriers, Innovative Networks of Care"
- 2001 Institute of Medicine Site Visit Presentation, Denver, CO: "Denver Health: A Health System Integrating Safety Net Services"
- 2001 Wishard Hospital Board, Indianapolis, IN: "Measures of Denver Health's Success"
- 2003 Greater Detroit Area Health Council, Detroit, MI: Denver Health, A Model for Access
- 2003 Seventh Caring for Colorado's Medically Underserved Conference, Denver, CO: Preserving the Safety Net in Challenging Times
- 2003 RW Johnson Presentation, Denver, CO: Perfecting the Public Safety Net System: Applicability for a National Model
- 2004 Colorado Healthcare Strategy and Management (CHSM): Preserving the Safety Net in Challenging Times
- 2004 ABIM (American Board of Internal Medicine): Changing the Culture for Quality: What are the Roles and Responsibilities of Academic Health Centers?
- 2005 World Health Congress, Washington, DC: Clinical Transformation through Information Technology
- 2005 AHRQ, Washington, DC: Applying Redesign Successes in Non-Medical Industries to Hospital Redesign
- 2005 Healthcare Financial Management Association, Denver, CO: How Hospital Health Systems CEO's View Leadership

- 2005 The Denver Future Forum, Denver, CO: The Crisis of the Medically Uninsured
- 2005 National Association of Public Hospital and Health Systems, Santa Fe, NM: Redesign Inpatient Care: Tools to Use
- 2005 Academy Health, Boston, MA: The Journey of Transforming Health Care Delivery at Denver Health
- 2005 Association of Academic Health Centers, Washington, DC: Maximizing the Educational Mission of Safety Net Hospitals,
- 2006 University of Colorado Health Sciences Center, Denver, CO: Redesigning Health Care: A National Imperative, A Local Initiative
- 2006 The Commonwealth Fund, Commission on High-Performance System, Denver, CO: Denver Health: A High Performing Health System
- 2006 National Association of Public Hospital and Health Systems, Fellows Class, San Antonio, TX: System Transformation
- 2006 AHRQ Action Presentation, Washington, DC: Managing and Evaluating Rapid Cycle Process Improvements as Vehicles for Redesign
- 2006 AHRQ Panel, Washington, DC: Emerging Approaches to Drive Change in Health Care: Use of Lean
- 2006 National Association of Public Hospital and Health Systems, Monterey, CA: The Role of the Public Safety Net in Disaster Preparedness
- 2007 New York Health and Hospitals, New York, NY: Health System Transformation
- 2007 American College of Healthcare Executives, New Orleans, LA: Improving Hospital Flow through Process Redesign
- 2007 NAPH Annual Meeting, Santa Fe, NM: CEO Strategies for Strengthening Capital Hill Relationships:
- 2008 Commonwealth Fund Congressional Retreat, Washington, DC: Denver Health, A High Performing Health System
- 2008 LEAN HealthCare West, 3rd Annual LEAN Health Care Conference, Denver, CO: The Power of the C Suite
- 2008 New York Health and Hospitals, New York, NY: Becoming LEAN
- 2008 University of Michigan, Ann Arbor, MI: Entrepreneurship for Public Health Within an Integrated Health Care System
- 2008 Democratic National Convention, Denver, CO: Rocky Mountain Roundtable, Health and Wellness Roundtable
- 2008 Colorado Summit on Health Care, Denver, CO: DH Innovative Solutions for Improving Health Care Delivery
- 2009 University of Colorado, Denver, CO: Issues in Public Health
- 2009 University of Colorado, Boulder, CO: Healthcare in America, Colorado and Denver
- 2009 NAPH, Washington, DC: Responding to Economic Crisis, Preparing for Health Reform

- 2009 Colorado Women's Forum, Denver, CO: Implementing LEAN at Denver Health
- 2009 University of Pennsylvania, Philadelphia, PA: From Bedside to Boardroom
- 2009 U.S. House of Representatives, Committee on Energy and Commerce, Subcommittee on Health: Congressional Testimony on Health Care Reform
- 2010 Siemens Healthcare Executive Forum , Florida Keynote Inspired Healthcare Leadership and Healthcare Transformation
- 2010 Boston Medical Center, Boston Mass. Patient Safety in a Safety Net Institution
- 2010 Harvard Medical School, Cambridge, Mass. Could a Safety Net System be a Model for Health Reform
- 2010 American Society of Nephrology Christopher R. Blagg Lectureship, Denver, CO. American Healthcare: Issues, Reform, Response
- 2010 Colorado Performance Excellence Conference Denver, CO Keynote Delivering Results by Using Lean within the Baldrige Framework
- 2010 University of Denver Undergraduate Commencement Address
- 2011 National Health Policy Forum Washington, D.C. The ACA and the Safety Net
- 2011 Shingo Prize for Operational Excellence, Ohio The Role of the Leadership Team in Implementation and Sustainment of Lean
- 2011 Institute for Healthcare Improvement Triple Aim Conference Denver, CO Perfect Care: A Journey
- 2011 Veterans' Administration Healthcare System, Medical Leadership Conference, Chicago, Ill. Two Healthsystems on a Journey
- 2011 Association of American Medical Colleges Petersdorf Lectureship Denver, CO, Denver Health's Transformation Journey
- 2012 Institute of Medicine Roundtable on Value and Science-Driven Health Care, Washington, D.C. Delivering Value in the Safety Net
- 2012 Geisinger Healthsystem Danville, PA Caring for Vulnerable Populations
- 2012 ABIM Foundation Forum Rancho Palos Verdes, CA Operating Principles of Change and Improvement
- 2012 Association of Manufacturing Excellence Chicago, Ill Leading Lean Transformation in a Healthcare Institution
- 2013 Commencement Address- University of Colorado School of Medicine

- 2013 Leading a Lean Enterprise Transformation-New York Federal Reserve
- 2013 University of Colorado, School of Medicine Graduation Speech
- 2013 Lean: A Solution to American Health Care National Quality Forum
- 2014 HMORN Phoenix, AZ The Intersection of Health Care System Redesign and Research in the Safety Net

Research Grants:

Vapor Inhalation Treatment Program
Bonfils Foundation - \$85,000
December 1985 to December 1986

Human Polycystic Kidney Disease (#DK34039)
National Institutes of Health
Co-Principal Investigator
April 1, 1985 to March 31, 1990; \$3,381,470
Principal Investigator
April 1, 1991 to March 30, 1996; \$2,666,407
Principal Investigator
April 1, 1996 to June 30, 1999; \$3,792,550

Community Voices: Health Care for the Underserved
W.K. Kellogg Foundation/Colorado Trust
Principal Investigator - \$5,000,000
July 1, 1997 to June 30, 2007

AHRQ Integrated Delivery System Research Network
Racial Disparity
Principal Investigator - \$244,761
November 1, 2001 to October 31, 2002

AHRQ Task Order #7
Improving Efficiency Through Hospital Redesign
Principal Investigator - \$349,919
October 1, 2003 to October 30, 2004

AHRQ Task Order #11
Managing and Evaluating Rapid Cycle Process Improvements as Vehicles for Hospital System Redesign
Principal Investigator - \$349,997
June 1, 2005 to November 30, 2006

Caring for Colorado Foundation
Getting it Right: Perfecting the Patient Experience
Principal Investigator - \$114,319
February 28, 2005 to February 27, 2006

Caring for Colorado Foundation

Getting it Right: Perfecting the Patient Experience: Phase II
Principal Investigator - \$137,994
July 14, 2006 to July 13, 2007

Rose Community Foundation
Getting it Right: Perfecting the Patient Experience: Talent Profiling
Principal Investigator - \$300,000
June 1, 2005 to May 31, 2006

Center for Medicare and Medicaid Innovation
Twenty First Century Care: Ambulatory Care Redesign
Principal Investigator-\$ 19.5 million
2012 (transferred PI to Dr. Paul Melinkovich with retirement from Denver
Health)

Original Articles:

1. Gabow PA, Lacher JW, Neff TA. Tubulointerstitial and glomerulonephritis associated with rifampin: Report of a case. JAMA 235:2517-2518, 1976.
2. Cronin R, Kaehny W, Miller P, Stables D, Gabow PA, et al. Renal cell carcinoma: Unusual systemic manifestations. Medicine 55:291-311, 1976.
3. Gabow PA, de Torrente A, Holt S, Kelly G. Arteriofistula from drug abuse: Implications for hemodialysis. JAMA 235:2220-2221, 1976.
4. Henrich WL, Goldberg J, Lucas M, Gabow PA. Adrenal insufficiency after unilateral radical nephrectomy. Urology 8:584-585, 1976.
5. Anderson RJ, Potts DE, Gabow PA, et al. Unrecognized adult salicylate intoxication. Ann Intern Med 85:745-748, 1976.
6. Gabow PA, Hanson T, Popovtzer MM, Schrier RW. Furosemide-induced reduction in ionized calcium in hypo parathyroid patients. Ann Intern Med 86:579-581, 1977.
7. Anderson RJ, Linas SL, Berns AS, Henrich WK, Miller TN, Gabow PA, Schrier RW. Nonoliguric acute renal failure. N Engl J Med 296:1134-1138, 1977.
8. Miller TR, Anderson RJ, Linas SL, Berns AS, Henrich WL, Gabow PA, Schrier RW. Urinary diagnostic indices in acute renal failure. Ann Intern Med 89:47-50, 1978.
9. Gabow PA, Anderson RJ, Potts DE, Schrier RW. Acid-base disturbances in the salicylate-intoxicated adult. Arch Intern Med 138:1481, 1978.
10. Gabow PA, Moore WS, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intern Med 90:338-340, 1979.

11. Moss AH, Gabow PA, Kaehny WD, Haut L, Haussler MD. Fanconi's syndrome and distal renal tubular acidosis after glue sniffing. *Ann Intern Med* 92:69-70, 1980.
12. Gabow PA, Kaehny WD, Fennessey PV, Goodman SI, Gross PA, Schrier RW. Diagnostic importance of an increased serum anion gap. *N Engl J Med* 303:854-858, 1980.
13. Streicher HZ, Gabow PA, Moss AH, Kono D, Kaehny WD. Syndromes of toluene sniffing in adults. *Ann Intern Med* 94:758-762, 1981.
14. Gabow PA, Kaehny WD, Kelleher S. The spectrum of rhabdomyolysis. *Medicine* 61:141-152, 1982.
15. Benedetti RG, Heilman JK III, Gabow PA. Nephrotoxicity following single dose mithramycin therapy. *Am J Neph* 3:277-278, 1983.
16. Lowenstein SR, Cramer J, Ratner K, Oliva PB, Gabow PA. The role of alcohol in new-onset atrial fibrillation. *Arch Intern Med* 143:1882-1885, 1983.
17. Anderson R, Gabow PA, Gross P. Urinary chloride concentration in acute renal failure. *Miner Electrolyte Metab* 10:92-97, 1984.
18. Gabow PA, Ikle DW, Holmes JH. Polycystic kidney disease: Prospective analysis of nonazotemic patients and family members. *Ann Intern Med* 101:238-247, 1984.
19. Gabow PA, Hutt DM, Baker S, Craig SR, Gordon JB. Comparison of hospitalization between nursing home and community residents. *J Am Geriatr Soc* 33:524-529, 1985; also *Geriatrics Digest* 3:11-12, 1986.
20. Gabow PA, Clay K, Sullivan JB, Lepoff R. Organic acids in ethylene glycol intoxication. *Ann Intern Med* 105:16-20, 1986.
21. Wilson PD, Schrier RW, Breckon RD, Gabow PA. A new method for studying human polycystic kidney disease epithelia in culture. *Kidney Int* 30:371-378, 1986.
22. Harris DCH, Gabow PA, Linas S, Rosendale DE, Guggenheim SP, Schrier RW. Prevention of hypercalcemia-induced renal concentrating defect and tissue calcium accumulation by phosphate restriction in the rat. *Am J Physiol* 251:F642, 1986.
23. Sedman A, Bell P, Manco-Johnson M, Schrier R, Warady BA, Heard EO, Butler-Simon N, Gabow PA. Autosomal dominant polycystic kidney disease in childhood: A longitudinal study. *Kidney Int* 31:1000-1005, 1987.
24. Pretorius DH, Lee ME, Manco-Johnson ML, Weingast GR, Sedman AB, Gabow PA. Diagnosis of autosomal dominant polycystic kidney disease in utero and in the young infant. *J Ultrasound Med* 6:249-255, 1987.

25. Gabow PA. Ethylene glycol intoxication. *Am J Kidney Dis* 11:277-279, 1988.
26. Everson GT, Scherzinger A, Berger-Leff N, Reichen J, Lezotte D, Manco-Johnson M, Gabow PA. Polycystic liver disease: Quantitation of parenchymal and cyst volumes from computed tomography images and clinical correlates of hepatic cysts. *Hepatology* 8:1627-1634, 1988.
27. Bell PE, Hossack KF, Gabow, PA, Durr JA, Johnson AM, Schrier RW. Hypertension in autosomal dominant polycystic kidney disease. *Kidney Int* 34:683-690, 1988.
28. Hossack KF, Leddy CL, Johnson AM, Schrier RW, Gabow PA. Echocardiographic findings in autosomal dominant polycystic kidney disease. *N Engl J Med* 319:907-912, 1988.
29. Kimberling WJ, Fain PR, Kenyon JB, Goldgar D, Sujansky E, Gabow PA. Linkage heterogeneity of autosomal dominant polycystic kidney disease. *N Engl J Med* 319:913-918, 1988.
30. Gabow PA, Kaehny WD, Johnson AM, Duley IT, Manco-Johnson M, Lezotte DC, Schrier RW. The clinical utility of renal concentrating capacity in polycystic kidney disease. *Kidney Int* 35:675-680, 1989.
31. Kaehny WD, Tangel DJ, Johnson AM, Kimberling WJ, Schrier RW, Gabow PA. Uric acid handling in autosomal dominant polycystic kidney disease with normal filtration rates. *Am J Med* 89:49-52, 1990.
32. Winter SD, Pearson JR, Gabow PA, Schultz AL, Lepoff RB. The fall of the serum anion gap. *Arch Intern Med* 150, 1990.
33. Sujansky E, Kreutzer SB, Johnson AM, Lezotte DC, Schrier RW, Gabow PA. Attitudes of at-risk and affected individuals regarding presymptomatic testing for autosomal dominant polycystic kidney disease. *Am J Med Genet* 35:510-515, 1990.
34. Gabow PA, Johnson, AM, Kaehny WD, Manco-Johnson ML, Duley IT, Everson GT. Risk factors for the development of hepatic cysts in autosomal dominant polycystic kidney disease. *Hepatology* 11:1033-1037, 1990.
35. Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, Manco-Johnson M, Schrier RW. Renal structure and hypertension in autosomal dominant polycystic kidney disease. *Kidney Int* 38:1177-1180, 1990.
36. Gabow PA, Phillips MG. Psychogenic adipsia in a patient with psychotic depression. *Am J Kidney Dis* 15:592-594, 1990.
37. Chapman AB, Thickman D, Gabow PA. Percutaneous cyst puncture in the treatment of cyst infection in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 16:252-255, 1990.

38. Kumar S, Kimberling WJ, Gabow PA, Shugart YY, Pieke-Dahl S. Exclusion of autosomal dominant polycystic kidney disease type II (ADPKD2) from 160 cM of chromosome 1. *J Med Genet* 27:697-700, 1990.
39. Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. *N Engl J Med* 323:1091-1096, 1990.
40. Drake TR, Henry T, Marx J, Gabow PA. Severe acid-base abnormalities associated with cocaine abuse. *J Emer Med* 8:331-334, 1990.
41. Granot Y, Van Putten V, Przekwas J, Gabow PA, Schrier RW. Intra-and extra-cellular proteins in human normal and polycystic kidney epithelial cells. *Kidney Int* 37:1301-1309, 1990.
42. Wilkins-Haug L, Gabow PA. Toluene abuse during pregnancy: Obstetric complications and perinatal outcomes. *Obstet Gynecol* 77:504-509, 1991.
43. Kumar S, Kimberling WJ, Gabow PA, Kenyon JB. Genetic linkage studies of autosomal dominant polycystic kidney disease: Search for the second gene in a large Sicilian family. *Hum Genet* 87:129-133, 1991.
44. Payne TH, Cohn DL, Davidson AJ, Henry TD, Schaefer JW, Gabow PA. Marked elevations of serum alkaline phosphatase in patients with acquired immunodeficiency syndrome. *J Acquir Immune Defic Syndr* 4:238-243, 1991.
45. Chapman AB, Gabow PA, Schrier RW. Reversible renal failure in polycystic kidney disease associated with converting enzyme inhibition. *Ann Intern Med* 115:769-773, 1991.
46. Wilson PD, Hreniuk D, Gabow PA. Abnormal extra-cellular matrix and excessive growth of human adult polycystic kidney disease epithelia. *J Cell Physiol* 150:360-369, 1992.
47. Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, Jones RH. Factors affecting the progression of renal disease in autosomal dominant polycystic kidney disease. *Kidney Int* 41:1311-1319, 1992.
48. Gabow PA, Duley I, Johnson AM. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 20:140-143, 1992.
49. Chapman AB, Rubinstein D, Hughes R, Stears JC, Earnest MP, Johnson AM, Gabow PA, Kaehny WD. Intracranial aneurysms in autosomal dominant polycystic kidney disease: A prospective study. *N Engl J Med* 327:916-920, 1992.
50. Bodenhamer J, Bergstrom BA, Brown D, Gabow PA, Marx JA, Lowenstein SR. Frequent ebulized beta-agonists for asthma: Effects on serum electrolytes. *Ann Emerg Med* 21:1337-1342, 1992.

51. Dobin A, Kimberling WJ, Pettinger W, Bailey-Wilson JE, Shugart YY, Gabow P. Segregation analysis of autosomal dominant polycystic kidney disease. *Genet Epidemiol* 10:189-200, 1993.
52. Fick GM, Johnson AM, Strain JD, Kimberling WJ, Kumar S, Manco-Johnson ML, Duley IT, Gabow PA. Characteristics of very early onset autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 3:1863-1870, 1993.
53. Chapman AB, Johnson AM, Gabow PA. Intracranial aneurysms in patients with autosomal dominant polycystic kidney disease: How to diagnose and who to screen. *Am J Kidney Dis* 22:526-531, 1993.
54. Kimberling WJ, Kumar S, Gabow PA, Kenyon JB, Connolly CJ, Somlo S. Autosomal dominant polycystic kidney disease: Localization of the second gene to chromosome 4q13-q23. *Genomics* 18:467-472, 1993.
55. Mehler PS, Kaehny WD, Fraser V, Miller S, Bost T, Lezotte DC, Gabow PA, Anderson RJ. Clinical effect of morning report. *Acad Med* 68 (7):547, 1993.
56. Fick GM, Duley IT, Johnson AM, Strain JD, Manco-Johnson ML, Gabow PA. The spectrum of autosomal dominant polycystic kidney disease in children. *J Am Soc Nephrol* 4:1654-1660, 1994.
57. Yium J, Gabow PA, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks: Clinical course and effects of sickle-cell hemoglobin. *J Am Soc Nephrol* 4:1670-1674, 1994.
58. Fick GM, Johnson AM, Gabow PA. Is there evidence for anticipation in autosomal dominant polycystic kidney disease? *Kidney Int* 45:1153-1162, 1994.
59. Chapman AB, Johnson AM, Gabow PA. Pregnancy outcome and its relationship to progression of renal failure in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5:1178-1185, 1994.
60. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5:1349-1354, 1994.
61. Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Dobin A, Gabow PA. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5:2032-2036, 1995.
62. Steiner C, Lezotte D, Gabow PA. Court-ordered alcohol treatment for patients with medical problems. *Am J on Addict* 4:127-132, 1995.
63. Mehler PS, McClellan MD, Lezotte D, Casper E, Gabow PA. Alcoholism: Methods to improve identification and intervention. *The West J of Med* 163:335-340, 1995.

64. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5:2048-2056, 1995.
65. Golin CO, Johnson AM, Fick GM, Gabow PA. Insurance for autosomal dominant polycystic kidney disease patients prior to end-stage renal disease. *Am J Kidney Dis* 27:220-223, 1996.
66. Kimberling WJ, Yium JJ, Johnson AM, Gabow PA, Martinez-Maldonado M. Genetic studies in a black family with autosomal dominant polycystic kidney disease and sickle-cell trait. *Nephron* 72:595-598, 1996.
67. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, Reynolds DM, Cai Y, Gabow PA, Pierides A, Kimberling WJ, Breuning MH, Deltas CC, Peters DJM, Somlo S. PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. *Science* 272: 1339-1342, 1996.
68. Hritz SA, Gabow PA. A peer approach to high-risk youth. *Soc Adol Med* 15:29-26, 1996.
69. Gabow PA, Kimberling WJ, Strain JD, Manco-Johnson ML, Johnson AM. Utility of ultrasonography in the diagnosis of autosomal dominant polycystic kidney disease in children. *J Am Soc Nephrol* 8:105-110, 1997.
70. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. *J Am Soc Nephrol* 8:1560-1567, 1997.
71. Chapman AB, Gabow PA. Hypertension in autosomal dominant polycystic kidney disease. *Kidney Int* 52:S71-S73, 1997.
72. Chapman AB, Johnson AM, Ranguet S, Hossack K, Gabow PA, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 8:1291-1297, 1997.
73. Gabow PA. Denver Health: Initiatives for survival. *Health Affairs* 16:24-26, 1997.
74. Gabow PA, Johnson AM, Sharp C. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 9:1908-1914, 1998.
75. O'Sullivan DA, Torres VE, Gabow PA, Thibodeau SN, King BF, Bergstralh EJ. Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 32:976-983, 1998.
76. Fick-Brosnahan G, Johnson AM, Strain JD, Gabow PA. Renal asymmetry in children with autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 34:639-645; 1999.
77. Gabow PA. From the bedside to the boardroom. *Sem Nephrol* 19(2):109-114; 1999.

78. Sharp C, Zeligman B, Johnson A, Duley I, Gabow PA. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without end-stage renal disease. *Am J Kidney Dis* 34: 863-868, 1999.
79. Stamm ER, Townsend R, Johnson AM, Garg K, Manco-Johnson M, Gabow PA. The frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 34:120-124; 1999.
80. Watnick T, Phakdeekitcharoen B, Johnson A, Gandolph M, Wang M, Briefel G, Klinger KW, Kimberling W, Gabow PA, Germino GG. Mutation detection of PKD1 identifies a novel mutation common to three families with severe disease. *Am J Hum Genet* 65:1561-1571, 1999.
81. Grampsas SA, Chandhoke PS, Fan J, Glass MA, Townsend R, Johnson AM, Gabow P. Anatomical and metabolic risk factors for nephrolithiasis in patients with autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 36:53-57, 2000.
82. Ecker T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Duley IT, Gabow PA, Schrier RW. Progress in blood pressure control in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 36:266-271, 2000.
83. Persu A, Devuyt O, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen-Dumoulin C. CF gene and cystic fibrosis transmembrane conductance regulator expression in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 11:2285-2296, 2000.
84. Chatha RK, Johnson AM, Rothberg PG, Townsend RR, Neumann HPH, Gabow PA. Von Hippel-Lindau disease masquerading as autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 37:852-858, 2001.
85. Fick-Brosnahan G, Tran ZV, Johnson AM, Strain JD, Duley IT, Gabow PA. Progression of autosomal dominant polycystic kidney disease in children. *Kidney Int* 59:1654-1662, 2001.
86. Steele AW, Eisert S, Gabow PA. Improvements in billing processes and information systems increase cash collections in a public health care system. *Health Care Manag.* 20:(1):29-36, 2001.
87. Ecker T, Edelstein CL, Fick-Brosnahan G, Johnson AM, Chapman AB, Gabow PA, Schrier RW. Diuretics versus angiotensin converting enzyme inhibitors in autosomal dominant polycystic kidney disease. *Am J Nephrol* 21(2):98-103, 2001.
88. Belz MM, Hughes RL, Kaehny WD, Johnson AM, Fick-Brosnahan GM, Earnest MP, Gabow PA. Familial clustering of ruptured intracranial aneurysms in autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 38:770-776, 2001.

89. Eisert S, Gabow PA. The Effects of Child Health Insurance Plan Enrollment on the Utilization of Health Care Services. *Pediatrics*, 110: 940-945, 2002.
90. Gabow PA, Eisert S, Wright RA. Denver Health: A Model for an Integration of a Public Hospital and Community Health Centers. *Ann Intern Med*. 138:143-149, 2003.
91. Belz MM, Fick-Brosnahan GM, Hughes RL, Rubinstein D, Chapman AB, Johnson AM, McFann KK, Kaehny WD, Gabow PA. Recurrence of intracranial aneurysms in autosomal dominant polycystic kidney disease. *Kidney Int*. 63 18224-1830, 2003.
92. Schrier R, Belz M, Johnson A, Kaehny W, Hughes R, Rubinstein. D, Gabow PA. Repeat Imaging for Intracranial Aneurysms in Patients with Autosomal Dominant Polycystic Kidney Disease with Initially Negative Studies: A Prospective Ten-Year Follow Up. *J AmSoc Nephrol* 15:1023-1028, 2004.
93. Swanson D, Gabow P, Dart RC. Evaluating Patient Compliance with Nurse Advice Line Recommendations and the Impact on Healthcare Costs. *Am J Manag Care* 2004; 10:534-542.
94. Steele A, Eisert S, Davidson A, Sandison T, Lyons P, Garrett N, Gabow PA , Ortiz E. Using Computerized Clinical Decision Support for Latent Tuberculosis Infection Screening. *Am J Prev Med* 2005;28(3).
95. Steele AW, Eisert S, Witter J, Lyons P, Jones MA, et al. 2005 The Effect of Automated Alerts on Provider Ordering Behavior in an Outpatient Setting, *PLoS Med* 2(9): e255.
96. Gabow P, Eisert S, Karkhanis A, Knight A, Dickson P. A Toolkit for Redesign in Health Care. *AHRQ Publication No. 05-0108-EF*; September 2005.
97. Thomas M, Waxmonsky J, Gabow P, Flanders-McGinnis G, Socherman R, Rost K. Prevalence of Psychiatric Disorders and Costs of Care Among Adult Enrollees in a Medicaid HMO. *Psychiatric Services* November 2005, Vol. 56, No. 11.
98. Steele AW, Witter J, Eisert S , Lyon P, Jones M, Gabow P, Ortiz E. The Effect of Automated Alerts on Provider Ordering Behavior in the Outpatient Setting. 2005 *PLoS Med* 2(9): e255.
99. Steele A, Eisert S, Davidson A, Sandison T, Lyons P, Garrett N, Gabow P, Ortiz E. Using Computerized Clinical Decision Support For Latent Tuberculosis Infection Screening, *American Journal of Preventive Medicine*, 2005;28 (3) April 2005.
100. Gabow P, Karkhanis A, Knight A, Dixon P, Eisert S, Albert, R. Observations of Residents' Work Activities for 24 Consecutive Hours: Implications for Workflow Redesign, *Academic Medicine*, Aug 2005, Vol 81: I 8, 766-775
101. Eisert S, Mehler P, Gabow P Can America's Urban Safety Net Systems be a Solution to Unequal Treatment? *Journal of Urban Health: Bulletin of the New York Academy of Medicine*, 10.1007/s11524-008-9296-5, 2008.

102. Reed B, McFann K, Kimberling WJ, Pei, Gabow PA, Christopher K, Petersen E, Kelleher C, Fain PR, Johnson A, Schrier RW. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history: *Am J Kidney Dis*, 2008 Dec; 52 (6): 1042-50. Epub 2008 Jul 21.
103. Eisert SL, Durfee MJ, Welsh A, Moore SL, Mehler PS, Gabow PA. Changes in insurance status and access to care in an integrated safety net healthcare system: *J Community Health*. 2009 Apr;34(2):122-B
104. Gabow, Patricia A. and Mehler, Philip S. A Broad And Structured Approach To Improving Patient Safety And Quality: Lessons From Denver Health. *Health Affairs*, 30, no.4 (2011):612-618; doi:10.1377/hlthaff.2011.0042

Reviews and Editorials:

1. Gabow PA, Anderson RJ, Schrier RW. Acute renal failure. *Cardiovasc Med* 2:1161-1175, 1977.
2. Gabow PA, Kaehny W. The anion gap: its meaning and clinical utility. *The Kidney* 12:No. 2, 1979.
3. Sedman AB, Gabow PA. Autosomal dominant polycystic kidney disease in children. *Dialogues in Pediatric Urology* 7: 4-5, 1984.
4. Gabow PA. Disorders associated with an altered anion gap. *Kidney Int* 27:472, 1985.
5. Gabow PA. How to avoid overlooking salicylate intoxication. *J of Critical Illness*; 77-85, October, 1986.
6. Gabow PA. The anion gap. *Consultant* 27:119-132, 1987.
7. Gabow PA, Grantham JJ, Bennett W, Childress JF, Cole B, Conneally PM, Gardner K, Kimberling WJ, Marsh F, Reeders S. Gene testing in autosomal dominant polycystic kidney disease: Results of National Kidney Foundation workshop. *The Am J Kidney Dis* 13:85-87, 1989.
8. Gabow PA. Sodium bicarbonate -- A cure or a curse? *J Crit Ill* 4:13-28, 1989.
9. Gabow PA. Autosomal dominant polycystic kidney disease -- More than a renal disease. *Am J Kidney Dis* 16:403-413, 1990.
10. Gabow PA. Genetic counseling in ESRD patients with polycystic kidney disease. *Semins Dialysis* 4:2-4, 1991.
11. Gabow PA. Polycystic kidney disease: Clues to pathogenesis. *Kidney Int* 40:989-996, 1991.

12. Gabow PA, Bennett WM. Renal manifestations: Complication management and long-term outcome of autosomal dominant polycystic kidney disease. *Semin Nephrol* 11:643-652, 1991.
13. Fick GM, Gabow PA. The urgent complications of autosomal dominant polycystic kidney disease. *J Crit Illness* 7:1905-1920, 1992.
14. Gabow PA. Autosomal dominant polycystic kidney disease. *N Engl J Med* 329:332-342, 1993.
15. Gabow PA. Autosomal dominant polycystic kidney disease. *Am J Kidney Dis* 22:511-512, 1993.
16. Yip L, Dart RC, Gabow PA. Concepts and controversies in salicylate toxicity. In *Emergency Medicine Clinics of North America: Concepts and Controversies in Toxicology*. Eds. Ford and Olshaker. W.B. Saunders Company. Philadelphia, PA, 1994.
17. Gabow PA. An outlook on the future of residency programs. *The Safety Net* 8:5-6, 1994.
18. Fick GM, Gabow PA. Natural history of autosomal dominant polycystic kidney disease. *Annu Rev Med* 45:23-29, 1994.
19. Fick GM, Gabow PA. Hereditary and acquired cystic disease of the kidney. *Kidney Int* 46:951-964, 1994.
20. Meehan M, Gabow PA. Service delivery excellence in a public hospital. *The Safety Net* 9:10-12, 1994.
21. Parsons PE, Kobayashi JS, Gabow PA. Futile care: Prevention and process. *J Crit Ill* 9:856-869, 1994.
22. Gabow PA. On quality. *The Safety Net* 12:2-3, 1998.
23. Gabow PA. You can't get along with them and you can't get along without them. *The Safety Net* 12:1-3, 1998.
24. Gabow, PA. Making the populations we serve less vulnerable. *The Safety Net* 12(3); 1998.
25. Gabow, PA. Making A Public Hospital Work. *Health Affairs*. 20: 182-187,2001.
26. Gabow P. Follow the evidence. Administrative rules, regulations should get comparative-effectiveness treatment: *Modern Healthcare* 2009 Dec 14; 39(50):25.
27. Gabow, Patricia A. "An 'open door' for the Vulnerable" *Modern Healthcare* August 8, 2011:24.

28. Delos Cosgrove, Michael Fisher, Gabow, Patricia , Gary Gottlieb, George Halvorson et al, "A CEO Checklist for High Value Health Care" Institute of Medicine of the National Academies June 5, 2012
29. Gabow, Patricia A. "Marshalling Leadership for High-Value Health Care – An Institute of Medicine Roundtable Report" JAMA XML PAGE: 1 SESS: 2, 2012

Books

1. Gabow PA. Fluid and Electrolytes: Clinical Problems and Their Solution. Little, Brown and Company; Boston, MA, 1983.
2. Gabow PA and Goodman P, The Lean Prescription: Powerful Medicine for our Ailing Healthcare System. In press.

Book Chapters:

1. Gabow PA. Disorders of potassium metabolism. In Renal and Electrolyte Disorders. Ed. Robert W. Schrier. Little, Brown and Company, 1977.
2. Gabow PA, Schrier RW. Water and sodium metabolism (hyponatremia and hypernatremia). Chapter 15. Textbook of Nephrology. Eds. Massry S, Glasscock, R. Elsevier North-Holland, Inc.; New York, New York, 1983.
3. Kaehny WD, Gabow PA. Pathogenesis and management of metabolic acidosis and alkalosis. In Renal and Electrolyte Disorders. Second Edition. Ed. Robert W. Schrier. Little, Brown and Company; Boston, MA, 1980.
5. Gabow PA, Peterson LN. Disorders of potassium metabolism. In Renal and Electrolyte Disorders. Second Edition. Ed. Robert W. Schrier. Little, Brown and Company; Boston, MA, 1980.
6. Gabow PA, Holmes JH. Early polycystic kidney disease. In Chronic Renal Disease. Eds. Cummings and Klahr. Plenum Publishing Company; New York, New York, 1984.
7. Kaehny WD, Gabow PA. Pathogenesis and management of metabolic acidosis and alkalosis. In Renal and Electrolyte Disorders. Third Edition. Ed. Robert W. Schrier. Little, Brown and Company; Boston, MA, 1986.
8. Gabow PA, Peterson LN. Disorders of potassium metabolism. In Renal and Electrolyte Disorders. Third Edition. Ed. Robert W. Schrier. Little, Brown and Company; Boston, MA, 1986.
9. Gabow PA. Cystic diseases of the kidney. In Current Therapy in Internal Medicine - 2. Eds. Theodore M. Bayless, Michael C. Brain, and Reuben M. Cherniack. B.C. Decker, Inc., Philadelphia, PA, 1986.

10. Grantham JJ, Gabow PA. Polycystic kidney disease. In Diseases of the Kidney. Fourth Edition Vol 1. Eds. Robert W. Schrier and Carl W. Gottschalk. Little, Brown and Company; Boston, MA, 1988.
11. Gabow PA. Cystic disease of the kidney. In Cecil Textbook of Medicine. Eighteenth Edition. Eds. James Wyngaarden and Lloyd H. Smith, Jr. W. B. Saunders Company; Philadelphia, PA, 1988.
12. Gabow PA. Pathophysiology of adult polycystic kidney disease. In Advances In Nephrology. Eds. Jean-Pierre Grunfeld, Jean Francois Bach, Jean-Louis Funck-Brentano, and Morton H. Maxwell. Year Book Publishers, Chicago, IL, 1989.
13. Gabow PA. Epidemiology of autosomal dominant polycystic kidney disease: Implications for genetic counseling. In Inheritance of Kidney and Urinary Tract Diseases. Eds. A. Spitzer and E. Avner. Kluwer Academic Publishers, Boston, MA, 1990.
14. Gabow PA. Autosomal dominant polycystic kidney disease. In The Cystic Kidney. Eds. Kenneth D. Gardner, Jr. and Jay Bernstein. Kluwer Academic Publishers, Boston, MA, 1990.
15. Gabow PA. Pathogenesis of hypertension in polycystic kidney disease. In Advances in the Pathogenesis of Polycystic Kidney Disease. Eds. Frank A. Carone and James W. Dobbie. Baxter Healthcare Corporation TP and T, Inc., Chicago, IL, 1990.
16. Granot Y, Summer SN, Van Putten VJ, Granot H, Gabow P, Schrier RW. Establishment of a continuous tissue culture system from human polycystic kidney disease cells. In Advances in the Pathogenesis of Polycystic Kidney Disease. Eds. Frank A. Carone and James W. Dobbie. Baxter Healthcare Corporation/TP and T, Inc.; Chicago, 1990.
17. Gabow PA, Wilkins-Haug L. Prediction of likelihood of polycystic kidney disease in the fetus when a parent has autosomal dominant polycystic kidney disease. In International Yearbook of Nephrology 1992. Eds. Vittorio E. Andreucci and Leon G. Fine. Springer-Verlag, London, 1991.
18. Gabow PA, Peterson LN. Disorders of potassium metabolism. In Renal and Electrolyte Disorders. Fourth Edition. Ed. Robert W. Schrier. Little, Brown and Company; Boston, MA, 1991.
19. Gabow PA. Cystic disease of the kidney. In Cecil Textbook of Medicine. Nineteenth Edition. Eds. James Wyngaarden, Lloyd H. Smith, Jr., and J. Claude Bennett. W. B. Saunders Company; Philadelphia, PA, 1992.
20. Kaehny WD, Gabow PA. Polycystic kidney disease: Clinical, radiologic, and genetic approaches to problems in diagnosis. In Contemporary Issues In Nephrology: Diagnostic Techniques in Renal Disease. Ed. Robert G. Narins. Churchill Livingstone, New York, NY, 1992.

21. Gabow PA. Hypo-Hyponatremia. In Oxford Textbook of Clinical Nephrology. Eds. S. Cameron, A.M. Davison, J.P. Grunfeld, D. Kerr and E. Ritz. Oxford University Press; Oxford, England, 1992.
22. Gabow PA, Grantham JJ. Polycystic kidney disease. In Diseases of the Kidney. Fifth Edition Vol I. Eds. Robert W. Schrier and Carl W. Gottschalk. Little, Brown and Company; Boston, MA, 1993.
23. Gabow PA. ADPKD in childhood. In Proceedings of the Fifth International Workshop on Polycystic Kidney Disease. Eds. P.A. Gabow and J.J. Grantham. Polycystic Kidney Disease Research Foundation; Kansas City, MO, 1993.
24. Schrier RW, Chapman AB, Gabow PA, Johnson AM. The pathogenesis and treatment of hypertension In ADPKD. In Proceedings of the Fifth International Workshop on Polycystic Kidney Disease. Eds: P.A. Gabow and J.J. Grantham. Polycystic Kidney Disease Research Foundation; Kansas City, MO, 1993.
25. Gabow PA, Bennett WM. Clinical aspects of autosomal dominant polycystic kidney disease. In Proceedings of the Fifth International Workshop on Polycystic Kidney Disease. Eds. P.A. Gabow and J.J. Grantham. Polycystic Kidney Disease Research Foundation; Kansas City, MO, 1993.
26. Gabow PA. Case study on autosomal dominant polycystic kidney disease. In Ethical and Legal Issues in Pedigree Research. Eds. M.S. Frankel and A.H. Teich. American Association for the Advancement of Science; Washington, DC, 1993.
27. Gabow PA. Polycystic and acquired cystic diseases. In Primer on Kidney Diseases. Ed. A. Greenburg. Academic Press, San Diego, CA, 1994.
28. Chapman AB, Gabow PA. Cystic diseases of the kidneys. Textbook of Nephrology. Eds. Shaul G. Massry and Richard J. Glassock. Williams and Wilkins; Baltimore, MD, 1995.
29. Duley I, Gabow P. PKD Patient's Manual: Understanding and Living with Autosomal Dominant Polycystic Kidney Disease. Polycystic Kidney Research Foundation; Kansas City, MO, 1995.
30. Gabow PA. Life is a series of useful lessons. Women in medicine and management. A mentoring guide. Eds. Deborah M. Shilian. American College of Physician Executives, Tampa, FL 1995.
31. Gabow PA. Cystic diseases of the kidney. Cecil Textbook of Medicine. Twentieth Edition, Eds. James Wyngaarden, Lloyd H. Smith, Jr. and J. Claude Bennett. W.B. Saunders Company; Philadelphia, PA, 1996.

32. Gabow PA. Definition and natural history of autosomal dominant polycystic kidney disease. In *Polycystic Kidney Disease*. Eds. Michael L. Watson and Vicente E. Torres. Oxford Univ Press, Oxford, England, 1996.
33. Gabow PA, Grantham JJ. Polycystic kidney disease. In *Diseases of the Kidney, Sixth Edition Vol 1*. Eds. Robert W. Schrier and Carl W. Gottschalk. Little, Brown and Company, Boston, MA, 1997.
34. Gabow PA. Renal cystic disease. In *Principles of Medical Biology*. Eds. Edward Bittar and Neville Bittar. JAI Press, Inc., Greenwich, CT, 1997.
35. Gabow PA. Polycystic and acquired cystic diseases. In *Primer on Kidney Diseases. Second Edition*. Ed. Arthur Greenberg, Academic Press, San Diego, CA, 1998.
36. Gabow PA. Cystic diseases of the kidney. In *Inherited Disorders of the Kidney*. Eds. Stephen H. Morgan and Jean-Pierre Grunfeld. Oxford Univ Press, Oxford, England, 1998.
37. Gabow PA. The Ability to See the Truth. In *The Heart of Leadership: Inspiration and Practical Guidance for Transforming Your Health Care Organization*. AHA Press, Chicago, Ill, 2010.

Abstracts:

1. Gabow PA, Linas SL, Rosendale D. The effect of cimetidine (CM) on potassium (K) tolerance. *Clin Res* 32:66A, 1984.
2. Gabow PA, Hutt DM, Baker S, Craig S, Gordon J. Outcome of patients admitted to a hospital from a nursing home (NH). *Clin Res* 32:30A, 1984.
3. Sedman A, Butler N, Gabow PA. Autosomal dominant polycystic kidney disease in children. *Kidney Int* 27:226; 1985.
4. Wilson P, Breckon R, Schrier R, Gabow P. Abnormal characteristics of human polycystic kidney epithelia grown in vitro. *Kidney Int* 27:153; 1985.
5. Gabow PA, Clay KL. Glycolic acid in human ethylene glycol intoxication (EGI). *Western Society for Clinical Investigation*, 1985.
6. Gabow PA, Hutt DM, Baker S, Craig SR, Gordon JB. Comparison of hospitalization between nursing home and community residents. *International Synopses Periodical*, 1985.
7. Bell PE, Duley IT, Pretorius DH, Heard EO, Lezotte DC, Kaehny WD, Gabow PA. Urinary concentrating defect in polycystic kidney disease. *Clin Res* 34:589A, 1986.
8. Harris DCH, Gabow PA, Schrier RW. Mechanism of protection of phosphate restriction on the concentration defect of hypercalcemia. *Clin Res* 34, 1986.

9. Hossack KF, Leddy CL, Schrier RW, Gabow PA. Incidence of cardiac abnormalities associated with autosomal dominant polycystic kidney disease. *Kidney Int* 31:203, 1987.
10. Kimberling W, Fain P, Gabow PA, Kenyon J, Sujansky E. Confirmation of linkage of autosomal dominant polycystic kidney disease to chromosome 16. *Kidney Int* 31:206, 1987.
11. Gabow PA, Heard E, Pretorius D, Duley I, Bell P, Kaehny W, Schrier RW. Relationship between renal structure and hypertension in autosomal dominant polycystic kidney disease. *Kidney Int* 31:297, 1987.
12. Bell P, Hossack K, Heard E, Durr J, Gabow PA, Schrier RW. Atrial natriuretic factor in normotensive and hypertensive patients with autosomal dominant polycystic kidney disease. *Kidney Int* 31:295, 1987.
13. Duley I, Gabow PA, Manco-Johnson M, Heard E, Bell P, Kaehny W, Schrier RW. Relationship between renal structure and concentrating ability in autosomal dominant polycystic kidney disease. *Kidney Int* 31:197, 1987.
14. Kaehny W, Bell P, Earnest M, Stears J, Gabow PA. Family clustering of intracranial aneurysms in autosomal dominant polycystic kidney disease. *Kidney Int* 31:204, 1987.
15. Wilson PD, Hagen K, Schrier RW, Gabow PA. Analysis of cellular and molecular defects in polycystic kidney disease using a new in vitro model of human cystic cell culture. *Kidney Int* 31:186, 1987.
16. Everson GT, Scherzinger A, Berger Leff N, Manco-Johnson M, Gabow PA. Polycystic liver disease: Validation of a method for measuring liver and cyst volume. *Clin Res* 35:184A, 1987.
17. Granot Y, Van Putten V, Summers S, Granot H, Gabow P, Schrier R. The biosynthesis of intra- and extra-cellular proteins by cultured human polycystic kidney cells. *Clin Res* 36:135A, 1988.
18. Gabow PA, Johnson AM, Duley IT, Lezotte, D, Kaehny WD. A proposed screening protocol for autosomal dominant polycystic kidney disease. *Kidney Int* 33:191, 1988.
19. Kaehny WD, Manco-Johnson M, Johnson AM, Tangel DJ, Gabow PA. Influence of sex on liver manifestations of autosomal dominant polycystic kidney disease. *Kidney Int* 33:196, 1988.
20. Tangel DJ, Kaehny WD, Duley IT, Johnson AM, Gabow PA. Hyperuricemia in autosomal dominant polycystic kidney disease. *Kidney Int* 33:211, 1988.
21. Bell PE, Hossack KF, Heard EO, Durr J, Gabow PA, Schrier RW. Atrial natriuretic factor in autosomal dominant polycystic kidney disease. *Clin Res* 35:543A, 1987.

22. Granot Y, Summer SN, Van Putten VJ, Granot H, Gabow PA, Schrier RW. Establishment of a continuous tissue culture system from human polycystic kidney cells. *Kidney Int* 33:191, 1988.
23. Hossack K, Bell P, Heard E, Durr J, Gabow P, Schrier R. Cardiac index and atrial natriuretic factor in hypertensive and normotensive patients with polycystic kidney disease. *Aust NZ J Med*, 17 suppl 2:587, 1987.
24. Earnest MP, Kaehny WD, Bell PE, Gabow PA. Familial clustering of intracranial aneurysms in autosomal dominant polycystic kidney disease. *Stroke* 18:292, 1987.
25. Hughes RL, Kaehny WD, Earnest MP, Gabow PA. Familial clustering of ruptured intracranial berry aneurysms in autosomal dominant polycystic kidney disease. *Neurology* 38 suppl 1: 132, 1988.
38. Geis JR, Thickman D, Gabow P, Manco-Johnson M. Comparison of ultrasound, CT and MR for imaging of autosomal dominant polycystic kidney disease. The 74th Scientific Assembly of the Radiological Society of North America, November/December 1988.
39. Everson GT, Leff N, Zogg D, Reichen J, Gabow P. Polycystic liver disease: Quantitative assessment of hepatic and cyst function. *Gastroenterology* 94:A538, 1988.
40. Chapman A, Johnson A, Kaehny W, Schrier R, Gabow P. Glomerular hyperfiltration: An early manifestation of autosomal dominant polycystic kidney disease. *Kidney Int* 35:203, 1989.
41. Sujansky E, Kreutzer S, Johnson A, Lezotte D, Schrier R, Gabow P. Attitudes on gene linkage analysis for prenatal testing of autosomal dominant polycystic kidney disease. *Kidney Int* 35:206, 1989.
42. Gabow P, Johnson A, Jones R, Lezotte D, Kaehny W, Schrier R. Hypertension: A determinant of renal function in autosomal dominant polycystic kidney disease. *Kidney Int* 35:205, 1989.
43. Johnson AM, Jones RH, Gabow PA. Method for group analysis of reciprocal serum creatinine vs. time plots. *Kidney Int* 37:249, 1990.
44. Gabow PA, Johnson AM, Kaehny WD, Chapman AB. Factors relating to renal functional deterioration in autosomal dominant polycystic kidney disease. *Kidney Int* 37:248, 1990.
45. Schrier RW, Chapman AB, Hiatt W, Johnson AM, Tschopp M, Gabow PA. Venoconstriction may explain increased plasma atrial natriuretic peptide and cardiac output in hypertensive autosomal dominant polycystic kidney disease. *Kidney Int* 37:251, 1990.

46. Chapman AB, Gabow PA, Johnson AM, Tschopp M, Schrier RW. Evidence for role of the renin-angiotensin-aldosterone system in hypertension of autosomal dominant polycystic kidney disease. *Kidney Int* 37:397, 1990.
47. Kaehny WD, Chapman AB, Stears JC, Gabow PA, Earnest MP. Prospective imaging study of asymptomatic intracranial aneurysms in polycystic kidney disease. *Kidney Int* 37:249, 1990.
48. Kimberling WJ, Pieke SA, Kenyon JB, Gabow PA. An estimate of the proportion of families with autosomal dominant polycystic kidney disease unlinked to chromosome 16. *Kidney Int* 37:249, 1990.
49. Chapman AB, Alfrey A, Miller N, Johnson AM, Gabow PA. Renal and cyst handling of endogenous lithium in autosomal dominant polycystic kidney disease. Presented at the XIth International Congress of Nephrology, Tokyo, Japan, July 15-20, 1990.
50. Chapman AB, Johnson AM, Gabow PA. Maternal and fetal outcomes of pregnancy in autosomal dominant polycystic kidney disease. Presented at the XIth International Congress of Nephrology, Tokyo, Japan, July 15-20, 1990.
51. Steiner C, Gabow PA. Alcoholism: Analysis of court-ordered intervention. American College of Physicians, 1989.
52. Chapman AB, Johnson AM, Kaehny W, Schrier R, Gabow PA. Comparison of creatinine clearance and glomerular filtration rate in patients with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 1:298, 1990.
53. Gabow PA, Duley I, Johnson AM, Chapman AB, Kaehny W. Clinical profiles of gross hematuria in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 1:299, 1990.
54. Wilkins-Haug L, Gabow PA. Chronic glue and paint sniffing during pregnancy: A population at risk for fetal and maternal morbidity. Society of Perinatal Obstetricians, 1990.
55. Bergstrom R, Brown D, Bodenhamer J, Gabow PA, Marx J, Lowenstein S. Effects of frequent beta₂ agonists on electrolytes in patients with acute asthma. *Clin Res*, 1990.
56. Yium J, Martinez-Maldonado M, Gabow PA, Kimberling WB. Autosomal dominant polycystic kidney disease in blacks, sickle-cell trait, clinical and genetic studies. Sixth International Interdisciplinary Conference On Hypertension In Blacks: Presented at the Health and Disease in Multi-cultural Societies: A Focus on Miscegenation, Salvador, Bahia, Brazil, 1991.
57. Chapman A, Johnson A, Duley I, Gabow PA. Hypertension occurs frequently in children with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 2:252, 1991.

58. Johnson A, Chapman A, Archer P, Kaehny W, Gabow PA. Application of the Cockcroft and Gault formula for creatinine clearance in normal and autosomal dominant polycystic kidney disease subjects. *J Am Soc Nephrol* 2:255, 1991.
59. Biller D, Pflueger S, Miller L, Guggenheim S, Kaehny W, Gabow PA. Autosomal dominant polycystic kidney disease in cats. *J Am Soc Nephrol* 2:250, 1991.
60. Gabow PA, Duley I, Strain J, Manco-Johnson M, Johnson A. Autosomal dominant polycystic kidney disease diagnosed in the first year of life. *J Am Soc Nephrol* 2:252, 1991.
61. Chapman AB, Gabow PA, Johnson AM, Schrier RW. Proteinuria is related to blood pressure levels in autosomal dominant polycystic kidney disease patients. Eds. P.A. Gabow and J.J. Grantham. PKR Foundation, Kansas City 130, 1993.
62. Fick G, Johnson A, Gabow PA. Health insurance and life insurance in patients with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 3:295, 1992.
63. Fick G, Johnson A, Duley I, Strain J, Gabow P. Relationship between structure and function in autosomal dominant polycystic kidney disease children. *J Am Soc Nephrol* 3:295, 1992.
64. Yium JJ, Gabow PA, Johnson A, Kimberling W, Martinez-Maldonado M. Autosomal dominant polycystic kidney disease in blacks with ESRD: Frequency, clinical course and effects of sickle-cell hemoglobin. *J Am Soc Nephrol* 3:305, 1992.
65. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Elevated plasma aldosterone concentrations occur frequently in hypertensive autosomal dominant polycystic kidney disease patients with normal renal function. *J Am Soc Nephrol* 3:530, 1992.
66. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Renal renin activity in hypertensive autosomal dominant polycystic kidney disease patients. Presented at the XIIth International Congress of Nephrology, Jerusalem, Israel, June 13-18, 1993.
67. Chapman AB, Johnson AM, Gabow PA, Schrier RW. Microalbuminuria in hypertensive autosomal dominant polycystic kidney disease patients with left ventricular hypertrophy. *J Am Soc Nephrol* 4:260, 1993.
68. Fick GM, Johnson AM, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 4:262, 1993.
69. Fick GM, Johnson AM, Duley IT, Gabow PA. Is there clinical evidence for anticipation in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 4:262, 1993.
70. Kimberling WJ, Kumar S, Gabow PA. Identification of chromosome site of autosomal dominant polycystic kidney disease unlinked to chromosome 16. *J Am Soc Nephrol* 4:816, 1993.

71. Woo HH, Chandhoke PS, Gabow PA. Evaluation of patients with autosomal dominant polycystic kidney disease and urolithiasis. Presented at the 73rd Annual Meeting of the South Central Section of the American Urological Association, Inc., Vancouver, British Columbia, August 27-31, 1994.
72. Fick GM, Johnson AM, Gabow PA. Liver cysts in sibpairs with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5:645, 1994.
73. Gabow PA, Johnson A, Kimberling W, Velidi M, Fowler T, Strain J. Utility of ultrasonography in children in families with chromosome 16 autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 5:646, 1994.
74. Chapman AB, Johnson AM, Gabow PA, Schrier RW. The role of parental hypertension in the frequency and age of onset of HBP in autosomal dominant polycystic kidney disease offspring. *J Am Soc Nephrol* 5:643, 1994.
75. Chapman A, Johnson A, Rubinstein D, Stears J, Hughes R, Gabow P. Autosomal dominant polycystic kidney disease patients are at increased risk for recurrent intracranial aneurysms. *J Am Soc Nephrol* 6:718, 1995.
76. Chapman A, Johnson A, Gabow P, Schrier R. Patients with a rate of loss of renal function in hypertensive and normotensive autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 6:1220, 1995.
77. Damodarasamy M, Dobin A, Gabow P, Johnson A, Kimberling W. Detection of frequent mutations in the PKD1 gene. *J Am Soc Nephrol* 6:1199, 1995.
78. Gabow P, Johnson A, Strain J. Factors affecting renal growth in children with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 6:2172, 1995.
79. Golin C, Johnson A, Gabow P. Intra-family variability in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 6:1215, 1995.
80. Golin C, Johnson A, Manco-Johnson M, Gabow P. Factors affecting renal growth in adults with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 6:1222, 1995.
81. Gabow P. Factors affecting renal survival in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 6:1214, 1995.
82. Fan J, Chandhoke PS, Glass MA, Woo H, Johnson AM, Gabow PA. Urinary citrate and oxalate excretion in polycystic kidney disease patients with and without renal stones. Annual Meeting of the American Urological Association, Inc., Orlando, Florida, May 4-9, 1996. (Presentation)

83. Fan J, Chandhoke PS, Glass MA, Woo H, Johnson AM, Gabow PA. Urinary excretion of citrate and oxalate in patients with autosomal dominant polycystic kidney disease. South Central Section of AUA, 1996. (Presentation)
84. Gabow PA, Johnson A. Factors relating to urinary protein excretion in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 7:1613, 1996.
85. Gabow PA, Johnson A, Kimberling W, Overbeck L. Relationship of mutations in the autosomal dominant polycystic kidney disease gene with clinical manifestations in autosomal dominant polycystic kidney disease patients. J Am Soc Nephrol 7:1613, 1996.
86. Glass, MA, Chandhoke PS, Fan J, Johnson AM, Gabow PA. Renal cyst characteristics in polycystic kidneys with and without stones. Annual Meeting of the American Urological Association, Inc., Orlando, Florida, May 4-9, 1996. (Presentation)
87. Glass, MA, Chandhoke PS, Fan J, Johnson AM, Gabow PA. Characteristics of renal cysts and the incidence of urolithiasis in patients with autosomal dominant polycystic kidneys disease. South Central Section of AUA, 1996. (Presentation)
88. Hughes R, Chapman A, Rubinstein D, Stears J, Johnson A, Gabow P. Recurrent intracranial aneurysms in autosomal dominant polycystic kidney disease. Stroke 27:178; 1996. (Presentation)
89. Chapman A, Raynolds M, Johnson A, Sharp C, Gabow PA. Evidence for genetic activation of the renin-angiotensin-aldosterone system in affected parents and very early onset autosomal dominant polycystic kidney disease offspring. NIDDK Workshop on Polycystic Kidney Diseases, 1997.
90. Gabow P. PKD1 gene: Clinical implications. Sydney, Australia: XIVth International Congress of Nephrology, 1997.
91. Gabow PA, Zeligman B, Johnson A. Evaluation of colonic diverticular disease in autosomal dominant polycystic kidney disease without ERSRD. J Am Soc Nephrol 8:372A, 1997.
92. Sharp C, Johnson A, Strain J, Gabow P. Clinical outcomes in children with very early onset autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8: 380A-381A, 1997.
93. Stamm E, Townsend R, Garg K, Johnson A, Manco-Johnson M, Gabow P. The frequency of ovarian cysts in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8:381A, 1997.
94. Heifner JK, Guay-Woodford LM, Johnson A, Gabow P. Comparison of autosomal dominant polycystic disease in African Americans versus Caucasian patients. J Am Soc Nephrol 9:375A, 1998.

95. Chatha R, Johnson A, Gabow P. Comparison of clinical manifestations of autosomal dominant polycystic kidney disease in Hispanic and Caucasian patients. *J Am Soc Nephrol* 9:372A, 1998.
96. Sharp C, Johnson A, Gabow P. The occurrence of spontaneous mutations in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 9:382A, 1998.
97. Fick-Brosnahan G, Raynolds M, Johnson A, Gabow P. Is the renin-angiotensin-aldosterone-system a significant modifier of autosomal dominant polycystic kidney disease renal disease severity? *J Am Soc Nephrol* 9:373A, 1998.
98. Watnick T, Phakdeekitcharoen B, Gandolph M, Johnson A, Gabow P, Kimberling W, Overbeck L, Landes G, Klinger K, Germino GG. Mutation detection of PKD1 exons 15-21 using locus specific reagents. *J Am Soc Nephrol* 9:384A, 1998.
99. Ecder T, Edelstein CL, Brosnahan GM, Johnson AM, Gabow PA, Schrier RW. Progress in the blood pressure control in hypertensive patients with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 10:415A, 1999.
100. Ecder T, Edelstein CL, Brosnahan GM, Johnson AM, Gabow PA, Schrier RW. Effect on renal function of diuretics versus angiotensin converting enzyme inhibitors in hypertensive patients with autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 10:415A, 1999.
101. Fick-Brosnahan G, Johnson AM, Strain JD, Duley IT, Gabow PA. Patterns of disease in siblings of children with very early onset autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 10:416A, 1999.
102. Fick-Brosnahan G, Johnson AM, Strain JD, Duley IT, Gabow PA. Parental hypertension is associated with increased renal disease severity in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 10:416A, 1999.
103. Fick-Brosnahan G, Tan Z, Johnson A, Strain D, Gabow PA. Determinants of renal growth in ADPKD children. Workshop Polycystic Kidney Disease 2000; May 11-12, 2000; Leiden, Netherlands.
104. Belz MM, Brosnahan GM, Johnson AM, Rubinstein D, Gabow PA. Recurrence of intracranial aneurysms in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 11:386A, 2000.
105. Pei Y, Johnson A, Lupea D, He N, Kairong W, Gabow P. Genetic epidemiology of elderly patients with polycystic kidney disease. *J Am Soc Nephrol* 11:396A, 2000.
106. Persu A, Lannoy N, Materne R, Brosnahan G, Gabow PA, Pirson Y, Verellen C, Devuyt O. The CF gene and CFTR expression in autosomal dominant polycystic kidney disease. *J Am Soc Nephrol* 11:397A, 2000.

107. Eisert S, Carrillo E, Gabow P, Steiner J, Neuzil P, Palmer C, Mushlin A. Addressing the impact of Racial and Ethnic Disparities on Access, Use, and Outcomes of Care Between Health Systems. Academy Health, June 2003, Nashville, TN.
108. Steele AW, Eisert S, Ortiz E, Lyons P, Sandison T, Gabow P. Encoded Guidelines for Targeted Latent Tuberculosis Screening Using an Electronic Medical Record, American Medical Informatics Association Annual Convention, November 2003, Washington, DC.
109. Eisert S, Steele AW, Ortiz E, Lyons P, Sandison T, Gabow P. Using Encoded Guidelines to Improve Screening of Adult Patients at High Risk of Latent Tuberculosis Infection, Academy Health, June 2004, San Diego, CA.
110. Steele AW, Eisert S, Ortiz E, Lyons P, Witter J, Jones M, Gabow P. The Effect of Using Rules Technology with Computerized Provider Order Entry in Medication Error Reduction in an Outpatient Setting, Academy Health, June 2004, San Diego, CA.